{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/nausea-vomiting-in-pregnancy/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"81c02d2d-db72-591c-9cac-e581388698c4","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 37e080f5-5c5f-4b53-b43b-e3ff99b01c84 --><h2>Changes</h2><!-- end field 37e080f5-5c5f-4b53-b43b-e3ff99b01c84 -->","summary":null,"htmlStringContent":"<!-- begin item 09590010-c84d-4a73-a53c-6e9ada4735e3 --><!-- begin field 0eefff65-1ee8-42c7-82ec-8e8acb14802d --><p><strong>November 2020 </strong>— minor update. Restless legs syndrome added as an adverse effect of promethazine in line with updated manufacturer's SPC.</p><p><strong>February 2020 </strong>— minor update. Drug update: ondansetron. Exposure to ondansetron during the first trimester of pregnancy is associated with a small increased risk of the baby having a cleft lip and/or cleft palate.</p><p><strong>October 2018</strong> — minor update. New product: Xonvea 10 mg/10 mg (doxylamine succinate/pyridoxine hydrochloride) gastro-resistant tablets added to new product availability - now licenced for the treatment of nausea and vomiting in pregnancy. </p><p><strong>May to June 2017 </strong>— reviewed. A literature search was conducted in April 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs and observational studies published since the last revision of the topic. New recommendations include considering use of a validated questionnaire to assess the severity of nausea and vomiting of pregnancy; considering avoiding iron-containing preparations if they are exacerbating symptoms; and offering support in the form of self-help and support groups. There have been minor changes to the sections on when to admit or seek specialist advice; offering advice; and choice of antiemetic (the order of preference of antiemetic use). More detailed prescribing information has also been included.</p><!-- end field 0eefff65-1ee8-42c7-82ec-8e8acb14802d --><!-- end item 09590010-c84d-4a73-a53c-6e9ada4735e3 -->","topic":{"id":"5d1ac05e-2e14-5b50-9a55-84ebd62fb88a","topicId":"866e168a-d1cc-4f14-ae38-2264dad4909d","topicName":"Nausea/vomiting in pregnancy","slug":"nausea-vomiting-in-pregnancy","lastRevised":"Last revised in November 2020","chapters":[{"id":"2ed30ea1-6303-508e-bc93-066f8ffbbba6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"81163ec6-a53e-53b1-9990-910cceb0be62","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9f99e883-ffa1-5d97-b703-d5bfbd68f8d5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"81c02d2d-db72-591c-9cac-e581388698c4","slug":"changes","fullItemName":"Changes"},{"id":"845aae6a-8e35-57f1-b583-4763434044df","slug":"update","fullItemName":"Update"}]},{"id":"21afb631-a6c0-5829-b00a-3b33bef92b50","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"61081bb4-4afa-59ad-8401-21a133c7ac1e","slug":"goals","fullItemName":"Goals"},{"id":"5e20514d-0378-56ab-a9c4-6adb3b054200","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5af11c90-393d-59dd-9a48-c750bc1a8a14","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"51bcef1b-8089-52c9-92cc-1fa55932d88b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef8fc985-dc5b-58a5-a2ff-ca6e9d55cfb8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f559ccd0-5b31-5044-9e75-d75ab6224e12","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2664bbce-4231-58ba-94b3-9154bbe463ce","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"474f1c82-889d-5487-9620-c2c4c6869f1b","slug":"definition","fullItemName":"Definition"},{"id":"8eb8a14e-f0bc-5bde-941f-077c2ebf80e8","slug":"causes","fullItemName":"Causes"},{"id":"6086e58d-ce8f-56ba-8bc9-6769de656e20","slug":"associated-factors","fullItemName":"Associated factors"},{"id":"843ada21-2019-53fe-96b9-02ac02e7d0f2","slug":"prevalence","fullItemName":"Prevalence"},{"id":"87b6f2c0-0cd6-59f3-9359-e145dc966385","slug":"complications","fullItemName":"Complications"}]},{"id":"d56e419a-1cce-586b-b99b-a5b8a8990006","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1f17249a-f4a8-55a7-aac0-221f3958f18f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b917da16-f352-5806-8109-438dbc9bbf0b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"92cdc482-cd10-5234-96f9-a47cf0d7a2d1","fullItemName":"Management","slug":"management","subChapters":[{"id":"110c4bdc-fe27-5536-9a99-bfbcf04edc46","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"93dd4a9b-e268-51a6-ad4d-89d5e9f8a3ab","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f416e06b-d171-5ff0-8c08-5bc1edd42843","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"130049ea-689b-545a-a2c3-05f0dd6e75a9","slug":"metoclopramide","fullItemName":"Metoclopramide"},{"id":"b1e3f566-e2f8-55a2-989a-e0a05d5ec1e2","slug":"ondansetron","fullItemName":"Ondansetron"},{"id":"5ab79693-69e2-58b9-b27b-5ccf74d1a7b5","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"715f035d-267f-5933-b2b0-7d3ee3bd6430","slug":"promethazine","fullItemName":"Promethazine"}]},{"id":"85b35812-d5b1-58c1-83b2-54c180386588","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1a1884de-e81c-54af-b11f-6b0868c50cc8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8a6cb0f6-92e2-57f4-9a1e-bf9e54371e08","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dc13c44-10ce-581a-a0a4-039b81c0c21e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cb1eb43f-2d9f-59be-8318-3bd84b8d0c3f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b024ff4-e12a-55bd-ae23-668d6ca9e645","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e5cef950-067b-517f-9adb-2be42bf3be6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"dbe95893-89e8-5737-9b03-95b5280f9823","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9f99e883-ffa1-5d97-b703-d5bfbd68f8d5","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"7790c360-0328-5774-b102-c906ec1af662","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 69196343-9877-4ff5-929d-dd87cbd1853d --><h3>Previous changes</h3><!-- end field 69196343-9877-4ff5-929d-dd87cbd1853d -->","summary":null,"htmlStringContent":"<!-- begin item a7d7371f-951d-41fd-a57d-6a2cbcfd5d53 --><!-- begin field 84ce067d-78bb-4a7f-b7f0-c92db4fab3e6 --><p><strong>September 2013 </strong>— minor update to the text to reflect current EMA recommendations regarding metoclopramide.</p><p><strong>January to June 2013 </strong>— reviewed. A literature search was conducted in December 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs and observational studies published since the last revision of the topic. There is one change to the recommendations – ondansetron is now recommended as a second-line anti-emetic.</p><p><strong>August 2012 </strong>— minor update. Minor typographical error corrected.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>November 2008 </strong>— update to text regarding the use of ginger and acupressure during pregnancy. These are now recommended by the National institute for Health and Clinical Excellence. Issued in December 2008.</p><p><strong>August 2008 </strong>— minor update to text regarding the safety of promethazine in pregnancy.</p><p><strong>February to May 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>March 2005 </strong>— reviewed. Validated in June 2005 and issued in July 2005.</p><p><strong>December 2001 </strong>— reviewed. Validated in March 2002 and issued in April 2002.</p><p><strong>January 1999 </strong>— written, replacing the guidance on <em>Hyperemesis of pregnancy</em>. Validated in March 1999 and issued in August 1999.</p><!-- end field 84ce067d-78bb-4a7f-b7f0-c92db4fab3e6 --><!-- end item a7d7371f-951d-41fd-a57d-6a2cbcfd5d53 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}